Abstract
Background and objectivesType 2 diabetes (T2D) is very prevalent among the elderly. Insulin therapy is often required for glycemic control. The association of starting this therapy with depressive symptoms as well the health-related quality of life (HRQoL) is unknown among the elderly patients.AimsEvaluate the association of starting insulin therapy depressive symptoms as well with HRQoL of elderly people with T2D.Methods36 T2D participants (67.9 % females, age 66.5 years ± 5.1) were recruited, 26 of whom completed the follow-up. Generic (Short-Form 36 Health Survey - SF-36) and specific (Problem Areas in Diabetes - PAID) HRQoL questionnaires, Beck Depression Inventory (BDI), clinical, laboratorial and socio-demographic data were recorded on baseline and 6 months after the beginning of insulin treatment.ResultsThere was a reduction in the BDI score after the use of insulin, which means an improvement in depressive symptoms (Before/After: median – 10.5 / 7; p = 0008). There were no statistically significant differences in HRQoL scores between the two time periods There was also a reduction in HbA1c (Before/After: median – 8.7/7.9). Otherwise, there were no statistically significant differences in: BMI (28.1/28.3); Abdominal circumference:(100.5/99.5) and chronic complications status.ConclusionInsulin therapy in elderly people with type 2 diabetes can lead to an improvement of depressive symptoms and does not seem to affect negatively HRQoL of the participants.
Highlights
Type 2 diabetes mellitus (T2D) is prevalent among adults, especially among elderly people
There was a reduction in the Beck Depression Inventory (BDI) score after the use of insulin, which means an improvement in depressive symptoms (Before/After: median – 10.5 / 7; p = 0008)
Generic (Short-Form 36 Health Survey - SF36) and specific (Problem Areas in Diabetes - PAID) health-related quality of life (HRQoL) questionnaires, Beck Depression Inventory (BDI), clinical, laboratorial and socio-demographic data were recorded at baseline and after 6 months of insulin therapy
Summary
36 T2D participants (67.9 % females, age 66.5 years ± 5.1) were recruited, 26 of whom completed the follow-up. Generic (Short-Form 36 Health Survey - SF-36) and specific (Problem Areas in Diabetes - PAID) HRQoL questionnaires, Beck Depression Inventory (BDI), clinical, laboratorial and socio-demographic data were recorded on baseline and 6 months after the beginning of insulin treatment
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.